795310-52-0

Basic information

• Product Name: 4-(3,5-DIMETHYL-4H-1,2,4-TRIAZOL-4-YL)PIPERIDINE
• Synonyms: 4-(3,5-Dimethyl-4H-1,2,4-triazol-4-yl)piperidine
• CAS NO: 795310-52-0
• Molecular Formula: C₉H₁₆N₄
• Molecular Weight: 180.25
• Mol File: 795310-52-0.mol

Chemical Properties

• Boiling Point: 300.939°C at 760 mmHg
• Flash Point: 135.804°C
• Appearance: /
• Density: 1.072g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.573
• Storage Temp.: 2-8°C
• PKA: 9.87±0.10(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 4-(3,5-DIMETHYL-4H-1,2,4-TRIAZOL-4-YL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,5-DIMETHYL-4H-1,2,4-TRIAZOL-4-YL)PIPERIDINE(795310-52-0)
• EPA Substance Registry System: 4-(3,5-DIMETHYL-4H-1,2,4-TRIAZOL-4-YL)PIPERIDINE(795310-52-0)

Safety Data

• RIDADR: UN1325
• HazardClass: 4.1
• PackingGroup: III
• Hazardous Substances Data: 795310-52-0(Hazardous Substances Data)

Usage

Uses

It is employed as intermediate for pharmaceutical.

InChI:InChI=1/C11H18N2/c1-9-3-4-10(2)13(9)11-5-7-12-8-6-11/h3-4,11-12H,5-8H2,1-2H3

Upstream product

• 50541-93-0 4-amino-1-benzylpiperidine 
• 1421071-14-8 (Z)-N'-(1-(1-benzylpiperidin-4-ylimino)ethyl)acetohydrazide 
• 50534-23-1 4-acetylamino-1-benzylpiperidine 
• 280111-37-7 1-benzyl-4-(3,5-dimethyl-[1,2,4]triazol-4-yl)-piperidine 

Relevant articles and documents

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

TRIAZOLYLPIPERIDINE DERIVATIVES AND USE THEREOF IN THERAPY

The present invention provides compounds of formula (I) Wherein R1 , R2, R3 , R4 , Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.

CHEMICAL COMPOUNDS

Compounds of formula (I): compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating CCR5 receptor activity in a warm blooded animal).